MedStorm Innovation

MedStorm Innovation is a medical technology company pioneering in developing a method based on analysing skin sympathetic nerve activity with acetyl-choline acting on muscarinic receptors mirrored by changes in skin conductance or emotional sweating to assess pain and nociceptive stimuli in all ages.

Med-Storm Innovation was founded in 1999. The main focus was to validate the PainSensor, also called Skin Conductance Algesimeter, when assessing pain and nociceptive stimuli. The company has MDR CE-certified indices to assess pain and nociceptive stimuli in the NICU, PICU, postoperatively and in the operating theatres, as well as awakening from unconscious when it is too little analgesia. The published studies show that the PainSensor technology can be used to assess regional NerveBlock and titrate the correct dose of analgesia during withdrawal symptoms. Med-Storm Innovation has obtained MDR-CE-certification on these indices. All the indices are in the PainSensor devices. More than 80 validation studies and 4 theses are published through peer-reviewed journals. All the studies show that the PainSensor Index increases during painful events and decreases when analgesia is given. There are now 12 approved patents on the algorithms of the indices and the proprietary sensors. Additionally, another 2 pendent IP-applications are in process. Through worldwide sales and grants from the Norwegian governments and the European committee, Med-Storm Innovation has been able to build sensitive and specific skin conductance device as a standalone model. The stand alone monitor is connected to all Philips patient monitors, Masimo ROOT, Mindray’s patient monitor when using their iPC and Draeger patient monitors when using SDC, as well as electronic patient records when using HL7.

The PainSensor is a low cost, wireless and wearable PainSensor with proprietary electrodes. Our accurate, real-time, and objective pain assessment offers a simple, real-time readout number to improve pain management.